Stockscreener 앱 받기
2.70
1.82%
-0.05
시간 외 거래:
2.69
-0.01
-0.37%
전일 마감가:
$2.75
열려 있는:
$2.74
하루 거래량:
3.03M
Relative Volume:
0.76
시가총액:
$588.33M
수익:
$35.54M
순이익/손실:
$-59.14M
주가수익비율:
-7.4237
EPS:
-0.3637
순현금흐름:
$-80.19M
1주 성능:
-2.17%
1개월 성능:
-19.88%
6개월 성능:
-36.02%
1년 성능:
-4.93%
1일 변동 폭
$2.66
$2.78
1주일 범위
$2.66
$2.995
52주 변동 폭
$2.66
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.70 | 588.33M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX Therapeutics stock gains 6.52 percent on September 23 - AD HOC NEWS
CytomX Therapeutics Inc (6C1) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
CytomX at Morgan Stanley conference: late-line crc push gains focus - Investing.com India
CytomX Therapeutics, Inc. Share Price Live Today – NASDAQ:CTMX Stock Price, Chart, News, History - Upstox
CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare ConferenceSlideshow - Seeking Alpha
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com South Africa
CytomX at cantor healthcare conference: pipeline gains, safety test ahead - investing.com
CytomX at Wells Fargo conference: epcam bet and cash strength - Investing.com
CytomX at Wells Fargo conference: epcam bet and cash strength By Investing.com - Investing.com UK
CTMXCytomX Therapeutics Inc Revenue Breakdown - Finviz
CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan
CytomX Therapeutics Inc. (CTMX) Peer Comparison – Compare with Others - Value Research
FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com Canada
FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com India
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - Yahoo Finance
CytomX (CTMX) Stock: Ends Up by 1.37% at $3.33 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateVanna Flow - siam.in
CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
CytomX Therapeutics (CTMX) Climbs 2.68% to $3.45, Trades Within Key Support-Resistance RangeHidden Order - vinanet.vn
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan
Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan
CytomX Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | CTMX | US23284F1057 - marketscreener.com
CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat
CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - MarketBeat
MSN Money - MSN
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha
CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa
CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK) - The Globe and Mail
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Buy" by Brokerages - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results - MarketBeat
CytomX Therapeutics, Inc. Stock 12‑Month Price Target Cut to $12.38, Implies 267% Upside - TradingView
State Street Corporation (CTMX) reports 5.4% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlight - GuruFocus
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... - Yahoo Finance
CytomX Therapeutics secures $37M from Regeneron amid Q2 revenue miss - scanx.trade
CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises - TradingKey
CytomX Therapeutics Q2 Earnings Call Highlights - marketbeat.com
CTMX Looks 1148.1% Overvalued on GF Value™ - GuruFocus
Earnings call transcript: CytomX misses Q2 2026 estimates as cash runway extends - Investing.com
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is CytomX Therapeutics Inc (CTMX) Facing Financial Headwinds Aft - GuruFocus
CytomX Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - The Manila Times
CytomX enrolls 113 patients; next colorectal cancer trial planned - Stock Titan
CytomX Therapeutics posts Q2 2026 results — $1.4M revenue, $25.2M operating expense, $330.3M cash - TradingView
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):